Sanofi-Aventis said it intends to contest in court the decision by the German health ministry to classify anti-obesity drug Acomplia as a non-reimbursable drug.The ministry recommendation was published in the Official Journal of the Government, prompting an immediate response by the drug maker.“Sanofi-Aventis considers the proposed reimbursement classification of Acomplia as unjustified given the profile of the drug,” the firm said in a statement.Sanofi has argued that, since it helps lower a person’s risk for developing diabetes and heart disease in addition to helping with weight loss, rimonabant should be covered under the state health insurance program.